ACE-tRNA Stop Codon Reassignment for Full-Length Protein Rescue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nonsense mutations in DNA that convert amino acid-encoding codons to stop codons result in truncated proteins, leading to genetic diseases like cystic fibrosis, muscular dystrophy, and β-thalassemia, as current therapies like PTC124 and aminoglycosides are inefficient and have limitations.
Innovation Solution
Development of modified transfer RNAs (tRNAs) with altered anticodons that recognize stop codons and deliver specific amino acids, enhancing interaction with Elongation Factor 1-alpha to stabilize and promote continued protein translation, using vectors for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nonsense suppressor tRNAs are used to suppress stop codons, then translation can be continued, but the suppression efficiency is low and protein production is incomplete
Solution Approach 1:
The patent modifies the tRNA molecule by changing parameters such as the anticodon sequence to recognize different stop codons (UAA, UAG, UGA) and altering the T-stem region nucleotides to enhance interaction with EF1α. These parameter changes in the tRNA structure directly improve suppression efficiency and protein production completeness.
Solution Approach 2:
The patent introduces EF1α as an intermediary protein that binds to the modified tRNA molecule. This intermediary interaction stabilizes the tRNA in the ribosome A-site and prevents its degradation, thereby enhancing the effectiveness of nonsense suppression and ensuring complete protein production.
2Productivity
If existing therapies like PTC124 and aminoglycosides are used to suppress stop codons, then translation can be partially restored, but the therapies are inefficient and have significant limitations
Solution Approach 1:
The patent replaces the chemical mechanism of existing therapies (PTC124 and aminoglycosides) with a biological mechanism using modified tRNAs. The tRNAs directly interact with the ribosome and stop codons through their anticodon regions, providing a more efficient and targeted approach to translation restoration without the harmful side effects of chemical drugs.
Solution Approach 2:
The modified tRNAs utilize the cell's own translation machinery and ribosomes to achieve nonsense suppression. The tRNAs are charged with amino acids by the cell's aminoacyl-tRNA synthetases and directly participate in the translation process, making the system self-sufficient and eliminating the need for external chemical drugs.
3Reliability
If tRNA molecules are modified to recognize stop codons, then premature termination can be suppressed, but the modified tRNAs may be degraded or unstable
Solution Approach 1:
The patent modifies the T-stem region of the tRNA molecule with specific nucleotide changes (e.g., G-C base pairs) that enhance the molecule's structural stability and resistance to degradation. These beforehand modifications cushion against the instability that would otherwise occur with stop codon recognition, ensuring the tRNA remains functional and stable in the cell.
Solution Approach 2:
EF1α serves as a protective intermediary that binds to the modified tRNA and shields it from degradation by cellular enzymes. This intermediary interaction stabilizes the tRNA's composition and ensures its longevity in the cell, thereby maintaining reliable nonsense suppression capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified tRNAs effectively suppress premature stop codons, restoring full-length protein production and improving therapeutic outcomes for genetic diseases by enhancing nonsense suppression activity.
Implementation Method 1
Each tRNA contains an 'anti-codon' region that hybridizes with a complementary codon on the mRNA
Implementation Method 2
the T-arm comprises a T-stem having nucleotides that interact with Elongation Factor 1-alpha (EF1α). EF1α recruits aminoacyl-tRNA to the ribosome and protects the tRNA from being deacylated
Implementation Method 3
A tRNA that carries its designated amino acid is called a 'charged' tRNA. If the tRNA is one of the 61 amino-acid-associated (i.e., not a stop-signal-associated) tRNAs, it will normally attach its amino acid to the growing peptide
Data Source
AI summary
In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, wherein the T-arm comprises nucleotides that interact with the elongation factor 1 alpha protein, and methods of use thereof. In certain embodiments, the present invention provides a modified transfer RNA (tRNA) comprising a T-arm, a D-arm, an anticodon-arm and an acceptor arm, (a) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UCA-3′ and recognizes TGA stop codons, and wherein the acceptor arm is operably linked to a arginine, tryptophan or glycine; (b) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-UUA-3′ and recognizes TAA stop codons, and wherein the acceptor arm is operably linked to a glutamine or, glutamate; or (c) wherein the anticodon-arm comprises a tri-nucleotide anticodon, wherein the anticodon is 5′-CUA-3′ and recognizes TAG stop codons, and wherein the acceptor arm is operably linked to a tryptophan, glutamate or glutamine.